ArticleWorld journal of urology2025
Long-term urinary complications in patients with localized prostate cancer treated with radiotherapy and/or radical prostatectomy.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough short-term complications of external beam radiotherapy (EBRT), radical prostatectomy (RP), or a combination of both (RP/EBRT) for prostate cancer have been extensively reported, data on long-term complications are under-reported. The primary objective was to compare the rates and severity of long-term genitourinary (GU) toxicity of EBRT, RP, and RP/EBRT. The secondary objective was to assess patient- and treatment-related risk factors for GU toxicity.
methodsWe retrospectively examined the charts of prostate cancer patients who received EBRT, RP, or RP/EBRT between 2010 and 2018 at Sherbrooke University Hospital Center (QC, Canada). Baseline patient characteristics, treatment-related information, and late GU complications (> 1-year post-treatment) were extracted.
resultsThe study included 1246 patients, of which 694 (55.7%), 380 (30.5%), and 172 (13.8%) received EBRT, RP, and RP/EBRT, respectively. Mean follow-up was 6.2 years (range, 1.5-12.2). Based on the Common Terminology Criteria for Adverse Events, EBRT group had 202 (29.1%) grade 2 and 38 (5.5%) grade 3 complications, compared to 66 (17.4%) grade 2 and 32 (8.4%) grade 3 for RP patients (p < 0.001). The RP/EBRT group had 58 (33.7%) grade 2 and 29 (16.9%) grade 3 complications (p < 0.001). No patient-related risk factor significantly increased the rate of GU toxicity, except for anticoagulation.
conclusionsPatients who underwent RP/EBRT had the highest rate and severity of complications. Although EBRT patients had a higher rate of GU toxicity, it was less severe than RP patients. This reinforces the importance of fully disclosing risks and types of complications when discussing treatment options.
Indexed as
Identifiers
40824494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.